XGN

Exagen Stock Analysis

AI Rating

Neutral
  • Quality1/10
  • Growth 5/10
  • Value 2/10
Exagen sales and earnings growth
XGN Growth
Neutral
  • Revenue Y/Y 19.65%
  • EPS Y/Y -12.05%
  • FCF Y/Y -3.31%
Exagen gross and profit margin trends
XGN Profitability
Neutral
  • Gross margin 58.30%
  • EPS margin -30.00%
  • ROIC 5Y -47.36%
Exagen net debt vs free cash flow
XGN Risk
Great
  • Debt / Equity 1.6
  • Debt / FCF 0.0
  • Interest coverage -3.6

Exagen stock volatility is in-line with the overall market. We give it a Great risk rating.

More Diagnostics & Research stocks ↗